| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-050 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于不向下修正"花园转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、截至2023年9月6日，浙江花园生物医药股份有限公司（以下简称为"公司"） 股票已出现连续三十个交易日中至少有十五个交易日的收盘价格低于当期转股价格的 85%的情形，触发"花园转债"转股价格向下修正条款。 2、公司第六届董事会第十七次会议审议通过了《关于不向下修正"花园转债"转 股价格的议案》，公司董事会决定本次不向下修正"花园转债"转股价格，下一触发 转股价格修正条件的期间从2023年9月7日重新起算，若再次触发"花园转债"转股价 格向下修正条款，届时公司董事会将再次召开会议决定是否行使"花园转债"的转股 价格向下修正权利。 一、可转换公司债券基本情况 经中国证券监督管理委员会证监许可[2023]252号文核准，公司于2023年3月6日向 不特定对象发行可转换 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-048 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于"花园转债"开始转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 经中国证券监督管理委员会《关于同意浙江花园生物高科股份有限公司向不特定对 象发行可转换公司债券注册的批复》（证监许可[2023]252号）核准，公司于2023年3月 6日向不特定对象发行可转换公司债券（以下简称"可转债"）1,200万张，每张面值为 人民币100元，发行总额为人民币120,000.00万元。 （二）可转换公司债券上市情况 经深圳证券交易所同意，公司120,000.00万元可转债已于2023年3月23日起在深圳 证券交易所挂牌上市交易，债券简称"花园转债"，债券代码"123178"。 （三）可转换公司债券转股期限 本次发行的可转换公司债券转股期自发行结束之日（2023年3月10日）起满6个月后 第一个交易日（2023年9月11日）起至可转换公司债券到期 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-047 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）于2023年8月22日召开了第六届董 事会第十六次会议及第六届监事会第十四次会议，审议通过了《关于回购公司部分股份方案 的议案》，本次回购尚需提交公司2023年第一次临时股东大会审议。具体内容详见公司于2023 年8月23日刊登在巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9号——回购 股份》的相关规定，公司已于2023年8月25日披露了公司董事会公告回购股份决议的前一个交 易日（即2023年8月22日）登记在册的前十名股东和前十名无限售条件股东的名称、持股数量 和持股比例情况；现将股东大会股权登记日（即2023 ...

关于花园转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300401 证券简称：花园生物 2、债券代码：123178 债券简称：花园转债 3、转股价格：15.05元/股 | | | 浙江花园生物医药股份有限公司 4、转股期限：2023年9月11日至2029年3月5日 5、自2023年8月17日至2023年8月30日，公司股票已有10个交易日的收盘价低于当 期转股价格15.05元/股的85%，如后续公司股票收盘价格继续低于当期转股价的85%， 预计将可能触发"花园转债"转股价格向下修正条件。若触发条件，公司将按照《浙 江花园生物医药股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》 （以下简称"《募集说明书》"）的约定及时履行后续审议程序和信息披露义务。敬 请广大投资者注意投资风险。 一、可转换公司债券基本情况 1、可转换公司债券发行情况 经中国证券监督管理委员会证监许可[2023]252号文核准，公司于2023年3月6日向 不特定对象发行可转换公司债券（以下简称"可转债"）1,2 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-045 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 | 序 | 持有人名称 | 持有数量（股） | 占总股本的比例（%） | | --- | --- | --- | --- | | 1 | 浙江祥云科技股份有限公司 | 144,376,377 | 26.20 | | 2 | 东方证券股份有限公司－中庚价值先锋股票型证券投资 基金 | 21,343,734 | 3.87 | | 3 | 邵君芳 | 16,650,037 | 3.02 | | 4 | 上海诺铁资产管理有限公司－合肥中安海通股权投资基 金合伙企业（有限合伙） | 13,830,500 | 2.51 | | 5 | 浙江花园生物医药股份有限公司－2022 年员工持股计划 | 7,674,790 | 1.39 | | 6 | 香港中央结算有限公司 | 5,426,682 | 0.98 | | 7 | 中科先行（北京）资产管理有限公司 | 5,000,000 | 0.91 | | 8 | #赖大建 | 3,85 ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-044 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 经浙江花园生物医药股份有限公司（以下简称"公司"）第六届董事会第十六次会 议审议通过，决定于2023年9月7日（星期四）召开公司2023年第一次临时股东大会。现 将会议相关事项通知如下： 一、会议召开的基本情况 1、股东大会届次：2023年第一次临时股东大会 2、召集人：董事会 3、会议召开的合法、合规性：本次股东大会的召开符合《公司法》《深圳证券交易 所创业板股票上市规则》等有关法律、法规、部门规章、规范性文件及《公司章程》的 规定。 4、会议召开的日期、时间 （1）现场会议时间：2023年9月7日（星期四）下午14:30； （2）网络投票时间：2023年9月7日；其中，通过深圳证券交易所交易系统进行网络 投票的时间为：2023年9月7日9:15-9:25、9:30-11:3 ...

| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2023-041 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 第六届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）第六届董事会第十六次会议 于2023年8月22日在公司会议室以现场结合通讯表决方式召开。会议通知于2022年8月18 日以微信、电子邮件等方式送达给全体董事。本次会议由公司董事长邵徐君先生召集并 主持，应出席董事9人，实际出席董事9人，公司监事、高管列席了会议。会议符合《公 司法》和《公司章程》的有关规定。 经参会董事表决，审议通过了如下议案： 一、审议通过了《关于回购公司部分股份方案的议案》 （一）回购股份的目的 基于对公司未来发展前景的信心及对公司价值的高度认可，为有效维护广大股东利 益，增强投资者信心，在综合考虑公司的经营状况、财务状况和股票二级市场状况后， 公司拟使用自有资金以集中竞价交易方式回购公司部分股份， ...

| 证券代码：300401 | 证券简称：花园生物 公告编号：2023-042 | | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | 浙江花园生物医药股份有限公司 第六届监事会会第十四次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）第六届监事会第十四次会议 于 2023 年 8 月 22 日在公司会议室以现场方式召开。会议通知于 2023 年 8 月 18 日以微 信及电子邮件等方式送达给全体监事。应出席监事 3 人，实际出席监事 3 人，符合《公 司法》和《公司章程》的有关规定。 会议经审议形成如下决议： 一、审议通过了《关于回购公司部分股份方案的议案》 监事会认为，公司本次回购股份方案符合《公司法》《证券法》《关于支持上市公 司回购股份的意见》《上市公司股份回购规则》等法律法规及《公司章程》等规定，本 次股份回购不会对公司经营活动、财务状况及未来发展产生重大影响，不会影响公司的 上市地位。该事项的决策程序符合相关法律法规和《公司章程》的规定，不存在损害公 司和中小股 ...

Financial Performance - The company's operating revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[22]. - The net profit attributable to shareholders was ¥117,207,847.77, down 60.54% from ¥297,037,103.38 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥105,610,344.41, a decline of 59.35% compared to ¥259,829,636.24 in the previous year[22]. - The net cash flow from operating activities was ¥136,429,704.54, representing a decrease of 57.78% from ¥323,154,330.91 in the same period last year[22]. - The gross profit margin for the pharmaceutical segment was 74.79%, down 5.62% from the previous year, with revenue declining by 29.95%[54]. - The company's revenue for the reporting period was ¥656,743,810.69, a decrease of 17.96% compared to ¥800,552,160.04 in the same period last year[52]. - The net profit for the first half of 2023 was CNY 117,207,847.77, a decrease of 60% compared to CNY 297,037,103.38 in the same period of 2022[166]. - The total revenue for the first half of 2023 was CNY 656,743,810.69, a decrease of 18% compared to CNY 800,552,160.04 in the same period of 2022[165]. Assets and Liabilities - Total assets at the end of the reporting period increased by 35.63% to ¥5,603,973,301.08 from ¥4,131,859,509.89 at the end of the previous year[22]. - The net assets attributable to shareholders rose by 14.27% to ¥2,939,222,838.92 from ¥2,572,174,931.79 at the end of the previous year[22]. - Total liabilities increased to ¥2,664,750,462.16, up from ¥1,559,684,578.10 at the end of last year[160]. - The company's total liability of CNY 2,059,175,953.45 as of June 30, 2023, compared to CNY 863,162,800.96 at the beginning of the year, indicating a significant increase[164]. Research and Development - Research and development investment increased by 41.08% to ¥47,634,586.43, driven by the strategy to enhance R&D capabilities[52]. - The company has established a stable and sustainable product development pipeline, transitioning from generic drugs to high-end generics with high technical barriers[49]. - The company has entered the registration process for 5 products and has 11 products under research, focusing on cardiovascular, digestive, and neurological systems[41]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new biopharmaceutical products in 2023[68]. - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on innovative drug formulations[136]. Market and Product Development - The company is focusing on the "one vertical and one horizontal" development strategy, increasing R&D investment and enhancing market integration[30]. - The company has identified five key pharmaceutical products for development, responding to market needs and regulatory changes[34]. - The company has three core production processes for Vitamin D3, which have received national awards and are at the international leading level[43]. - The company has completed a strategic acquisition of a smaller biotech firm for 300 million yuan, enhancing its product portfolio and market reach[68]. - New product launches are expected to contribute an additional 100 million yuan in revenue by the end of 2023, with three new products scheduled for release[68]. Strategic Initiatives - The company has built stable long-term strategic partnerships with internationally renowned manufacturers and distributors, enhancing its market channels[47]. - The company has actively responded to provincial procurement tenders, adding 8 new selected provinces for Valsartan Amlodipine Tablets during the reporting period[36]. - The company is considering strategic acquisitions to enhance its product portfolio and market reach[135]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[181]. Risks and Challenges - The company faces risks related to project investments, as uncertainties in construction progress, implementation, and outcomes could impact strategic development and operational scale[79]. - There is a heightened demand for high-quality talent in research, production, sales, and management due to the company's strategic development, which poses risks in management and human resource integration[79]. - The company faces risks from changes in medical reform policies, which could lead to a decline in operating performance if not adapted timely[80]. - There is a risk of declining drug prices due to government efforts to reduce medical costs, potentially impacting the company's profitability as average profit margins in the pharmaceutical industry may decrease[80]. Environmental and Compliance - The company has been recognized as one of the first four key industry environmental "leading" demonstration enterprises in Zhejiang Province[91]. - The company maintains compliance with environmental standards, with all monitored pollutants reported as not exceeding regulatory limits[91]. - The company has established a green development philosophy focusing on source reduction, process control, and end treatment of waste[91]. - The company invested CNY 1.74257 million in environmental governance and protection during the reporting period, and paid CNY 3,753.29 in environmental protection tax[96]. Shareholder Information - The company reported a cash dividend distribution of RMB 1.40 per 10 shares, totaling RMB 77,141,057.98 for the fiscal year 2022[149]. - The employee stock ownership plan includes 119 core management and key employees holding a total of 7,674,790 shares, representing 1.39% of the company's total equity[87]. - The company confirmed a share-based payment expense of approximately CNY 13.68 million for the employee stock ownership plan during the reporting period[88]. - The total number of shares outstanding is 551,007,557, with 98.41% being unrestricted shares[131].

Financial Performance - The company's revenue for Q1 2023 was ¥317,120,309.15, a decrease of 17.97% compared to ¥386,592,882.41 in the same period last year[6] - Net profit attributable to shareholders was ¥51,859,513.29, down 65.69% from ¥151,152,689.96 year-on-year[6] - Operating profit decreased to CNY 55,583,823.97, a decline of 68.7% from CNY 177,090,497.45 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were CNY 0.09, compared to CNY 0.28 in Q1 2022[24] - Total operating revenue for Q1 2023 was CNY 317,120,309.15, a decrease of 17.9% compared to CNY 386,592,882.41 in Q1 2022[22] - Total operating cost for Q1 2023 was CNY 269,882,876.30, up from CNY 234,074,731.77 in the same period last year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 43.11% to ¥139,756,862.80 from ¥245,658,562.83 in the previous year[6] - Cash inflow from operating activities was CNY 488,520,775.06, an increase from CNY 465,917,742.62 in Q1 2022[26] - Total cash outflow from operating activities amounted to CNY 348,763,912.26, up 58.2% from CNY 220,259,179.79 year-on-year[27] - Cash inflow from financing activities reached CNY 1,414,803,000.00, significantly higher than CNY 255,880,000.00 in the previous year, marking a growth of 451.5%[27] - Net cash flow from financing activities was CNY 1,276,076,114.69, an increase of 533.5% compared to CNY 201,208,438.42 in the prior year[27] - The ending balance of cash and cash equivalents was CNY 1,852,183,602.49, up from CNY 731,816,265.22 year-on-year, representing an increase of 153.5%[27] Assets and Liabilities - Total assets increased by 31.55% to ¥5,435,505,587.57 from ¥4,131,859,509.89 at the end of the previous year[6] - Total liabilities rose to CNY 2,491,668,937.63, compared to CNY 1,559,684,578.10 in the previous year[21] - As of March 31, 2023, total current assets reached 2,693,749,556.25 RMB, up from 1,387,028,622.29 RMB at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,685[13] - Zhejiang Xiangyun Technology Co., Ltd. holds 26.20% of shares, amounting to 144,376,377 shares, with 74,600,000 shares pledged[13] - The top ten shareholders hold a combined total of 207,000,000 shares, representing a significant portion of the company's equity[13] Expenses and Costs - The company reported a 74.35% increase in management expenses to ¥36,885,830.24, primarily due to higher equity incentive costs and depreciation[9] - Interest expenses surged by 82.24% to ¥9,315,186.44, attributed to increased costs from convertible bonds[9] - Cash paid for various operating activities rose by 306.72% to ¥99,617,099.13, mainly due to increased marketing expenses[10] - The company paid CNY 59,317,697.09 in taxes, which is an increase of 72.9% compared to CNY 34,329,539.86 last year[27] - Cash paid to employees was CNY 47,089,422.12, an increase of 18.5% from CNY 39,855,621.37 in the previous year[27] Investment and Development - The company has ongoing research and development efforts, as indicated by the increase in development expenditures to 30,209,385.93 RMB from 25,455,115.40 RMB[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[12] - The company plans to expand its market presence through the issuance of convertible bonds and potential new product developments[18] - The company issued 12 million convertible bonds at a face value of 100 RMB each, raising a total of 1.2 billion RMB, with a net amount of 1.186 billion RMB after expenses[18] Inventory and Cash Management - Inventory as of March 31, 2023, was 584,765,776.51 RMB, compared to 545,874,555.66 RMB at the beginning of the year[19] - The cash balance increased to 1,889,045,651.71 RMB from 554,909,447.09 RMB at the beginning of the year[19] Audit Status - The report for the first quarter was not audited[28]